超声电导靶向导入头孢菌素治疗慢性前列腺炎80 例的临床分析

目的:观察超声电导前列腺治疗仪经直肠导入二代头孢菌素(头孢呋辛)联合口服α受体阻滞剂(坦索罗辛)治疗Ⅲ型慢性前列腺炎的临床疗效。方法:将160例Ⅲ型慢性前列腺炎患者随机分为口服坦索罗辛组(对照组)和经直肠导入注射用头孢呋辛钠联合口服坦索罗辛组(治疗组)。对照组每天服药一次,共治疗6周。治疗组每天治疗1次,10天为一个疗程,两个疗程之间间隔7~10天,共3个疗程。采用慢性前列腺炎症状指数(NIH-CPSI)作为评分体系,分别观察和比较两组患者治疗前后的NIH-CPSI总分、疼痛评分、排尿评分和生活质量评分。结果:治疗组和对照组的总有效率分别为90.00%和68.8%,治疗组显著高于对照组(P0.05)。治疗后,两组患者的NIH-CPSI总评分、疼痛积分、排尿积分及生活质量评分都较治疗前显著改善(P0.05),且治疗组的症状改善较对照组更加明显,其各项评分均显著低于对照组(P0.05)。结论:采用超声电导前列腺治疗仪经直肠导入二代头孢菌素(头孢呋辛)联合口服α受体阻滞剂(坦索罗辛)可更加有效地治疗前列腺炎,改善患者的临床症状,并提高患者的生活质量,且毒副作用小,值得临床推广。     

电针配合中药熏蒸对慢性前列腺炎患者疗效和前列腺液中IL-17、TNF-α水平的影响

目的:探讨电针配合中药熏蒸对慢性前列腺炎患者疗效和前列腺液中白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)水平的影响。方法:选取2017年6月～2018年8月我院接收的慢性前列腺炎患者120例,根据随机数字表法分为观察组(n=60)和对照组(n=60)。对照组采用西医药物治疗,观察组采用电针配合中药熏蒸治疗。评价并比较两组疗效,比较两组患者治疗前后美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)评分、最大尿流率(Qmax)、平均尿流率(Qave)以及前列腺液IL-17、TNF-α水平。结果:观察组总有效率为90.00%,明显高于对照组的71.67%(P0.05)。治疗后,两组NIH-CPSI评分中的排尿症状、疼痛或不适、生活质量评分以及总分均明显降低,且观察组NIH-CPSI各维度评分及总分均低于对照组(P0.05)。治疗后,两组Qmax、Qave明显上升,且观察组Qmax、Qave明显高于对照组(P0.05)。治疗后,两组前列腺液IL-17、TNF-α水平明显降低,且与对照组比较,观察组IL-17、TNF-α水平明显更低(P0.05)。结论:电针配合中药熏蒸治疗慢性前列腺炎疗效确切,其能明显改善患者病情和尿流率,降低患者前列腺液中IL-17、TNF-α水平。     

高龄Ⅲ型前列腺炎患者血清和前列腺液中神经生长因子、炎性因子的表达水平及临床意义

目的:探讨高龄Ⅲ型慢性前列腺炎(CP)患者血清和前列腺液(EPS)中神经生长因子(NGF)、炎性因子的表达水平及其临床意义。方法:收集2015年5月~2016年12月我院收治的150例高龄Ⅲ型CP患者(CP组),其中ⅢA型81例,ⅢB型69例,另选择150例健康体检者作为对照(对照组)。采用双抗体夹心酶联免疫吸附法(ABC-ELISA)检测其血清、EPS中NGF、IL-8和TNF-α的表达水平,分析NIH-CPSI、NGF、IL-8和TNF-α之间的相关性。结果:CP组血清、EPS中TNF-α、IL-8、NGF水平均明显高于对照组(P0.05);与IIIB型患者比较,IIIA型患者TNF-α、IL-8水平明显升高(P0.05);EPS中TNF-α、IL-8、NGF水平均明显高于血清(P0.05)。IIIB型患者的NIH-CPSI症状评分明显低于IIIA型(P0.05)。CP患者EPS中NGF和TNF-α、IL-8均呈显著正相关(P0.05);血清中NGF和TNF-α、IL-8亦呈显著正相关(P0.05)。III型CP患者血清、EPS中,TNF-α、IL-8、NGF与NIH-CPSI呈显著正相关(P0.05)。结论:高龄III型CP患者血清、EPS中TNF-α、IL-8、NGF表达水平明显升高,且与NIH-CPSI明显相关,联合检测有助于评估III型CP患者的病情严重程度。     

宁泌泰胶囊联合盐酸莫西沙星治疗慢性前列腺炎患者的临床疗效及对血清TNF-α、IL-1β、M-CSF的影响

目的:探讨宁泌泰胶囊联合盐酸莫西沙星治疗慢性前列腺炎患者的临床疗效及对血清肿瘤坏死因子(TNF)-α、白介素(IL)-1β、巨噬细胞集落刺激因子(M-CSF)水平的影响。方法:选择2014年8月至2016年8月我院接诊的110例慢性前列腺炎患者,通过随机数表法分为观察组(n=55)和对照组(n=55)。对照组采用盐酸莫西沙星治疗,观察组联合宁泌泰胶囊治疗,均连续治疗2周。比较两组治疗前后慢性前列腺炎症状评分(NIH-CPSI)、前列腺液白细胞计数、血清TNF-α、IL-1β、M-CSF水平的变化及临床疗效。结果:治疗后,观察组临床疗效总有效率明显高于对照组(P0.05);两组NIH-CPSI评分、白细胞计数、血清TNF-α、IL-1β、M-CSF均较治疗前显著降低(P0.05),观察组以上指标均明显低于对照组(P0.05)。结论:宁泌泰胶囊联合盐酸莫西沙星治疗慢性前列腺炎的临床效果显著,可有效缓解临床症状,安全性高,其机制可能和降低血清TNF-α、IL-1β、M-CSF水平相关。     

单纯治疗慢性前列腺炎对其合并早泄的影响

目的:探讨单纯治疗慢性前列腺炎对其合并早泄的影响。方法:选择372例前列腺炎继发早泄的患者进行单纯针对前列腺炎的治疗,评价前列腺炎的治疗效果(包括前列腺炎症状评分(NIH-CPSI)、前列腺液常规等)及早泄的治疗效果(包括患者性生活满意度评分、配偶性生活满意度评分及阴道内射精潜伏期等)。结果:慢性前列腺炎经综合治疗后,患者的NIH-CPSI评分及前列腺液白细胞计数均显著降低(P0.05)。前列腺炎治愈或好转后,大多数患者的早泄情况得到明显改善,患者性生活满意度、配偶性生活满意度均较治疗前显著提高,阴道内射精潜伏期亦较治疗前明显延长,差异均具有统计学意义(P0.05)。结论:单纯治疗慢性前列腺炎继可使大部分患者并发的早泄明显改善,而对少数前列腺炎好转后早泄症状改善不明显者,可联合应用SSRIs等药物治疗。     

阿夫唑嗪联合盐酸莫西沙星治疗慢性前列腺炎的疗效及对血清TNF-α、IL-1β、PSP、M-CSF水平的影响

目的:探讨阿夫唑嗪联合盐酸莫西沙星治疗慢性前列腺炎的疗效及对血清肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、胰石蛋白(PSP)、巨噬细胞集落刺激因子(M-CSF)水平的影响。方法:选择2014年12月~2016年12月于我院就诊的98例慢性前列腺炎患者,按不同治疗方式分为对组与研究组,每组49例。对照组接受盐酸莫西沙星治疗,研究组基于对照组加以阿夫唑嗪治疗。观察并比较两组的临床疗效,治疗前后血清TNF-α、IL-1β、PSP、M-CSF水平、慢性前列腺炎症状指数评分(NIH-CPSI)的变化及不良反应的发生情况。结果:治疗后,研究组总有效率为95.91%,显著高于对照组(77.55%,P0.05)。两组治疗后血清TNF-α、IL-1β、PSP、M-CSF水平、NIH-CPSI评分均较治疗前显著下降,且研究组上述指标均明显低于对照组(P0.05)。两组不良反应的发生率比较差异无统计学意义(P0.05)。结论:阿夫唑嗪联合盐酸莫西沙星治疗慢性前列腺炎的疗效优于单用盐酸莫西沙星,可能与其显著降低血清TNF-α、IL-1β、PSP、M-CSF水平有关。     

泄浊通淋汤联合左氧氟沙星对慢性细菌性前列腺炎患者 IL-2、CRP和TNF-γ水平的影响

目的观察泄浊通淋汤联合左氧氟沙星对慢性细菌性前列腺炎患者IL-2、CRP和TNF-γ水平的影响。方法选择116例湿热下注型慢性细菌性前列腺炎患者为研究对象,随机分为研究组和对照组各58例。对照组患者口服左氧氟沙星治疗,研究组在对照组治疗的基础上口服泄浊通淋汤,两组患者均治疗4周。比较两组患者治疗效果、治疗前后EPS-WBC个数、NIH-CPSI评分以及血清IL-2、CRP和TNF-γ含量和不良反应发生情况。结果研究组患者治疗总有效率显著高于对照组(93.10%vs 77.59%,χ~2=5.583,P0.05)。研究组患者治疗后EPS-WBC个数、NIH-CPSI评分、血清IL-2、CRP和TNF-γ含量均低于对照组(均P0.05)。结论泄浊通淋汤联合左氧氟沙星可有效降低慢性细菌性前列腺炎患者EPS-WBC数量,改善NIH-CPSI评分,降低血清中IL-2、CRP和TNF-γ含量,且治疗期间不良反应少,值得临床推广应用。     

白芍总苷联合特拉唑嗪治疗非细菌性前列腺炎临床观察

目的:探讨白芍总苷联合特拉唑嗪治疗慢性非细菌性前列腺炎的临床效果.方法:将138例慢性非细菌性前列腺炎患者平均分为观察组和对照组,分别给予特拉唑嗪(2mg,每晚1次)+白芍总苷(0.6g,每天3次)和特拉唑嗪(2mg,每晚1次)治疗,12周后观察临床总体疗效、慢性前列腺炎症状指数(NIH-CPSI)评分及前列腺液常规.结果:观察组和时照组的临床总有效率、NIH-CPSI评分及前列腺液WBC计数均有显著改善,但观察组的改善程度均优于对照组.结论:白芍总苷联合特拉唑嗪治疗慢性非细菌性前列腺炎较单用特拉唑嗪疗效明显,值得临床推广.     

普适泰与地奥司明对老年慢性前列腺炎患者血清和前列腺液中MIP-2和MIP-1α的影响

目的:探讨普适泰联合地奥司明治疗老年慢性前列腺炎(CP)的临床效果及对患者血清和前列腺液巨噬细胞炎性蛋白-2(MIP-2)、巨噬细胞炎性蛋白-1α(MIP-1α)水平的影响。方法:选择我院2015年1月~2016年9月收治的126例老年CP患者,采取随机数字表将其分成两组。观察组(63例)给予普适泰联合地奥司明治疗,对照组(63例)予以普适泰治疗。记录比较两组临床疗效,治疗前后血清与前列腺液的MIP-2、MIP-1α水平;评价两组用药安全性。结果:治疗12周后,观察组总有效率为93.7%,较对照组明显升高(81.0%,P0.05)。与治疗前对比,两组治疗12周后血清和前列腺液中MIP-2、MIP-1α水平均显著下降(P0.01);且观察组治疗12周后血清与前列腺液中MIP-2、MIP-1α水平均显著低于对照组同期(P0.01)。两组不良反应发生率对比差异无统计学意义(P0.05)。结论:普适泰联合地奥司明治疗老年CP/CPPS能更安全有效地改善患者的临床症状,可能与其显著降低血清和前列腺液中MIP-2、MIP-1α水平有关。     

Ⅱ型前列腺炎患者前列腺结石与临床症状相关性分析

目的:讨论Ⅱ型前列腺炎患者前列腺结石、前列腺液白细胞数及临床症状相关性.方法:我院门诊2009年1月至2011年12月就诊的327例Ⅱ型前列腺炎患者纳入研究.所有患者治疗前均行前列腺液白细胞计数、经腹前列腺彩超和慢性前列腺炎症状指数评分(CPSI),将结果进行统计学分析.结果:所有Ⅱ型前列腺炎患者的前列腺结石直径和前列腺液中白细胞计数两者有相关性,差异具有统计学意义(P＜0.05),前列腺结石直径和NIH-CPSI评分、前列腺液白细胞计数和NIH-CPSI评分均无相关性(P＞0.05).根据前列腺结石直径将患者进行分组,不同组别的患者的前列腺液白细胞计数不同,其差异有统计学意义(P＜0.05),NIH-CPSI评分组间差异无统计学意义(P＞o.05).结论:Ⅱ型前列腺炎患者就诊时前列腺结石、前列腺液白细胞计数和前列腺炎患者临床症状无明细相关性,因此Ⅱ型前列腺炎患者前列腺结石情况和前列腺液白细胞计数一样不能作为独立因素评估前列腺炎的临床症状的严重性并用于指导治疗.     

Therapeutic Intervention for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): A Systematic Review and Meta-Analysis

Background

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has been treated with several different interventions with limited success. This meta-analysis aims to review all trials reporting on therapeutic intervention for CP/CPPS using the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI).

Methods

We searched Medline, PubMed, the Cochrane Pain, Palliative & Supportive Care Trials, the Cochrane Register of Controlled Trials, CINAHL, ClinicalTrials.gov, and the NIDDK website between 1947 and December 31, 2011 without language or study type restrictions. All RCTs for CP/CPPS lasting at least 6 weeks, with a minimum of 10 participants per arm, and using the NIH-CPSI score, the criterion standard for CP/CPPS, as an outcome measure were included. Data was extracted from each study by two independent reviewers. Gillbraith and I-squared plots were used for heterogeneity testing and Eggers and Peters methods for publication bias. Quality was assessed using a component approach and meta-regression was used to analyze sources of heterogeneity.

Results

Mepartricin, percutaneous tibial nerve stimulation (PTNS), and triple therapy comprised of doxazosin + ibuprofen + thiocolchicoside (DIT) resulted in clinically and statistically significant reduction in NIH-CPSI total score. The same agents and aerobic exercise resulted in clinically and statistically significant NIH-CPSI pain domain score reduction. Acupuncture, DIT, and PTNS were found to produce statistically and clinically significant reductions in the NIH-CPSI voiding domain. A statistically significant placebo effect was found for all outcomes and time analysis showed that efficacy of all treatments increased over time. Alpha-blockers, antibiotics, and combinations of the two failed to show statistically or clinically significant NIH-CPSI reductions.

Conclusion

Results from this meta-analysis reflect our current inability to effectively manage CP/CPPS. Clinicians and researchers must consider placebo effect and treatment efficacy over time and design studies creatively so we can more fully elucidate the etiology and role of therapeutic intervention in CP/CPPS.     

Erectile Dysfunction in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Outcomes from a Multi-Center Study and Risk Factor Analysis in a Single Center

The aim of this study was to investigate the prevalence of erectile dysfunction (ED) in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and explore the influence of UPOINT domains, National Institutes of Health-CP symptom index (NIH-CPSI) and other factors on ED prevalence. This was a prospective study of consecutive patients with CP/CPPS seen at 11 tertiary hospitals during January–July 2014. ED was diagnosed as a score of<21 on the International Index of Erectile Function (IIEF-5). Patients from one center were evaluated by the UPOINT system and NIH-CPSI. Each patient was assessed using clinical examination, asocio-demographic questionnaire, the Patient Health Questionnaire (PHQ), the Pain Catastrophizing Scale (PCS), NIH-CPSI and IIEF-5.1406 patients from 11 centers (mean age, 32.18 years; range 18–60 years) were enrolled. ED was found in 638/1406 patients (45.4%), and was categorized as mild in 291(45.6%), moderate in 297(46.6%) and severe in50(7.7%). 192 patients from one center(mean age,31.3 years; range 18–57 years) were further studied.IIEF-5 score correlated negatively with NIH-CPSI(r = 0.251), PHQ (r = 0.355) and PCS (r = 0.322)scores (P<0.001).PHQ score correlated positively with NIH-CPSI (r = 0.586) and PCS(r = 0.662) scores (P<0.001).NIH-CPSI, PHQ, PCS and IIEF-5 scores did not differ significantly between class IIIA and IIIB CP/CPPS. Multivariate logistic regression showed that UPOINT psychological (P) domain and NIH-CPSI symptom severity were independent risk factors for ED in CP/CPPS. It is concluded that psychological factors and symptom severity are independent risk factors for ED in CP/CPPS.     

Acupuncture for chronic prostatitis/chronic pelvic pain syndrome: study protocol for a randomized controlled trial

Background

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition affecting men of all ages. Acupuncture may be an effective treatment option for CP/CPPS, but evidence is limited. We propose to evaluate the effectiveness of acupuncture in a rigorously conducted trial.

Methods

Ten hospitals will recruit 440 participants with CP/CPPS in China from October 2017 to December 2019. Participants will be randomly allocated to acupuncture or sham acupuncture with a 1:1 ratio using computerized simple random sampling. The whole study consists of 2-week baseline, 8-week treatment, and 24-week follow up. Twenty 30-mintute sessions of acupuncture or sham acupuncture treatment will be provided between week 1 and 8. The two co-primary outcomes are the proportion of responders at week 8 and week 32. Secondary outcomes include proportion of responders in the two groups at different time points; change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score; change in the NIH-CPSI subscales; change in the International Prostate Symptom Score; change in the Hospital Anxiety and Depression Scale; expectation assessments; proportions of participants in each response category of the Global Response Assessment; change in the International Index of Erectile Function 5; change in the five-level EuroQol five-dimensional questionnaire and a visual analogue scale; and changes in peak and average urinary flow rate.

Discussion

This study will provide robust evidence on whether acupuncture is effective for relieving symptoms of CP/CPPS.

Trials registration

ClinicalTrials.gov, NCT03213938. Registered on 5 July 2017.

     

Sono-Electro-Magnetic Therapy for Treating Chronic Pelvic Pain Syndrome in Men: A Randomized,Placebo-Controlled,Double-Blind Trial

Objective

To assess the efficacy and safety of sono-electro-magnetic therapy compared to placebo in men with refractory CPPS.

Patients and Methods

In a randomized, placebo-controlled, double-blind single center trial, we assessed the effect of sono-electro-magnetic therapy in men with treatment refractory CPPS. Sixty male patients were randomly assigned to treatment with either sono-electro-magnetic (n = 30) or placebo therapy (n = 30) for 12 weeks. The primary outcome was a change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) from baseline to 12 weeks.

Results

The 12-week difference between sono-electro-magnetic and placebo therapy in changes of the NIH-CPSI total score was −3.1 points (95% CI −6.8 to 0.6, p = 0.11). In secondary comparisons of NIH-CPSI sub-scores, we found differences between groups most pronounced for the quality-of-life sub-score (difference at 12 weeks −1.6, 95% CI −2.8 to −0.4, p = 0.015). In stratified analyses, the benefit of sono-electro-magnetic therapy appeared more pronounced among patients who had a symptom duration of 12 months or less (difference in NIH-CPSI total score −8.3, 95% CI −14.5 to 2.6) than in patients with a longer symptom duration (−0.8, 95% CI −4.6 to 3.1; p for interaction = 0.023).

Conclusions

Sono-electro-magnetic therapy did not result in a significant improvement of symptoms in the overall cohort of treatment refractory CPPS patients compared to placebo treatment. Subgroup analysis indicates, however, that patients with a symptom-duration of 12 months or less may benefit from sono-electro-magnetic therapy, warranting larger randomized controlled trials in this subpopulation.

Trial Registration

ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00688506","term_id":"NCT00688506"}}NCT00688506     

The Effect of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) on Erectile Function: A Systematic Review and Meta-Analysis

Background

High prevalence of erectile dysfunction (ED) has been observed in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). However, whether or not CP/CPPS is a risk factor of ED remains unknown and controversial. Therefore, we conducted this systematic review and meta-analysis to evaluate the relationship between CP/CPPS and ED.

Methods

PubMed, Embase, Web of Science, and The Cochrane Library were searched up to November 11, 2014 to identify studies reporting the association between CP/CPPS and ED. Case–control, cohort and cross-sectional studies were included. Quality of the included studies was assessed. The odds ratio of ED and the mean difference of five-item International Index of Erectile Function (IIEF-5) score were pooled using a random effects model. Subgroup analysis and sensitivity analyses were performed.

Results

Three cross-sectional studies, two case–control studies, and four retrospective studies with 31,956 participants were included to calculate the pooled odds ratio of ED, and two studies with 1499 participants were included to calculate the pooled mean difference of IIEF-5 scores. A strong correlation was found between CP/CPPS and ED (pooled odds ratio: 3.02, 95% CI: 2.18–4.17, P < 0.01), with heterogeneity across studies (I ² = 65%; P < 0.01). A significant decrease in the IIFE-5 score was observed in the CP/CPPS group (pooled mean difference: −4.54, 95% CI: −5.11–−3.98; P < 0.01).

Conclusion

Our study indicates that patients with CP/CPPS have an increased risk of suffering from ED. Assessment of erectile function is necessary for the therapy of patients with CP/CPPS. Further evidence is necessary to confirm the relationship between CP/CPPS and ED.     

老年住院患者营养不良状况分析

目的:利用简易营养评价精法(short-form mini-nutritional assessment,MNA-SF)评价住院老年患者营养状况,并探讨老年患者营养状况与躯体功能的关系。方法:选取我院老年病及内科收治的年龄≥65岁的住院患者共104例,使用MNA-SF评价患者的营养状况,根据患者年龄、性别、慢性病等情况入组营养不良患者36例,营养良好患者68例,比较两组患者的饮食习惯、躯体功能,并对营养评分与握力、步速进行相关性分析。结果:与营养良好组相比,营养不良组进食肉食次数较少(16%vs 48%, P=0.012),握力[(11.67±9.89)kg vs (20.46±9.89)kg, P0.001]及步速(0.46±0.641m/s vs 1.16±0.65m/s,P0.001)均显著降低。老年住院患者MNA-SF得分与握力及步速呈显著正相关(r=0.562, P0.001)和(r=0.600,P0.001)。结论:住院老年患者的营养状况与进食肉食次数、握力和步速相关。     

n-6/n-3 多不饱和脂肪酸营养失衡对小鼠精子发生的影响

目的:探讨n-6/n-3多不饱和脂肪酸营养失衡对小鼠精子发生的影响。方法:健康的30只C57/B6雄鼠随机分为对照组(CON)、高脂组(HF)、花生四烯酸组(HF+AA)。喂食16周,做合笼实验并记录致孕率,通过精子动力分析仪检测小鼠精子活力和数量的变化,用Elisa试剂盒测血清中睾酮和甘油三酯水平。通过病理组织染色观察小鼠睾丸组织的形态学变化。利用Realtime-PCR的方法检测小鼠睾丸中Dazl基因表达水平的变化。结果:高脂组、花生四烯酸组与对照组相比精子活力[(16±0.01;12.33±2.83 vs72.2±12.73)%,P0.001],精子数量[(7.5±1.13;6±0.14 vs 13.87±0.35)million/m L,P0.001],致孕率[(28.57;14.29 vs 78.57)%,P0.001]及血清睾酮含量[(0.35±0.14;0.27±0.07 vs 3.51±0.7)ng/m L,P0.001]均显著性降低。高脂组、花生四烯酸组与对照组相比,血清中甘油三酯的含量显著增高[(0.74±0.04;0.74±0.04 vs 0.45±0.04)mmol/L,P0.001]。病理组织染色观察到花生四烯酸组小鼠睾丸组织出现了明显异形,曲细精管内部的初级精母细胞明显缺失,管腔中从初级精母细胞到精子的发生过程出现了变异,精子的数量也显著性下降。参与精子生成过程中的减数分裂前的有丝分裂增殖期、精原细胞的发育等过程的Dazl基因在高脂组和花生四烯酸组小鼠睾丸中的表达量与对照组相比显著降低(0.87±0.05;0.65±0.03 vs 1.07±0.04,P0.05)。结论:膳食中n-3/n-6多不饱和脂肪酸失衡会导致雄鼠精子发生发育的障碍     

重复经颅磁刺激对慢性精神分裂症患者认知功能影响的初步研究

目的:探讨重复经颅磁刺激(rTMS)对慢性精神分裂症患者认知功能的影响。方法:100例慢性精神分裂症患者,按照随机数字表法分为rTMS真刺激组和伪刺激组,每组各50例。采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评估患者治疗前后精神症状及不良反应;采用威斯康星卡片分类测验(WCST)及可重复的成套神经心理状态测量(RBANS)评价患者治疗前后认知功能。结果:治疗后,rTMS真刺激组PANSS总分、阳性量表分、阴性量表分、一般精神病理量表分均明显降低(P0.05),且均明显低于伪刺激组(P0.05),两组治疗前后及组间TESS评分无明显差异(P0.05);rTMS真刺激组WCST中的概念化水平百分数明显高于伪刺激组(P0.05),总时间及错误思考时间短于伪刺激组(P0.05);rTMS真刺激组RBANS中视觉广度与延迟记忆成绩明显提高(P0.05),且视觉广度明显高于伪刺激组(P0.05);rTMS真刺激组2例患者首次治疗后出现轻度不适症状,随访3个月所有患者均无不适主诉。结论:rTMS治疗对慢性精神分裂症患者的部分认知功能有一定的改善作用,且安全性较高,值得进一步研究。     

微波理疗对阑尾炎术后切口康复效果及生活质量的影响

目的:探讨微波理疗对阑尾炎患者术后切口康复效果及生活质量的影响。方法:选取2017年8月到2018年12月期间在秦皇岛市第一医院进行阑尾炎手术治疗的患者120例,按数表法将患者随机分为对照组(n=60)和研究组(n=60)。对照组患者术后接受常规换药治疗,研究组患者术后给予微波理疗。比较两组患者的术后恢复指标[肠鸣音恢复时间、切口愈合时间、肛门排气时间、住院时间、视觉模拟评分(VAS)]、并发症发生情况[切口感染、切口脂肪液化、腹胀、切口疼痛]以及生活质量。结果:研究组患者的肠鸣音恢复时间、切口愈合时间、肛门排气时间、住院时间分别为(18.19±3.57)h、(7.12±1.03)d、(21.42±3.54)h、(12.17±4.03)d,均短于对照组的(21.36±4.26)h、(8.09±1.36)d、(23.19±4.63)h、(14.39±4.62)d,差异有统计学意义(P0.05)。研究组的VAS评分为(3.56±1.05)分,低于对照组的(4.78±1.24)分,差异有统计学意义(P0.05)。研究组患者的切口感染、切口脂肪液化、腹胀、切口疼痛等并发症发生率为3.33%、8.33%、10.00%、16.67%,均低于对照组的16.67%、28.33%、23.33%、36.67%,差异有统计学意义(P0.05)。研究组患者的肠道症状、全身症状、情感功能的得分以及总分为(48.31±5.03)分、(46.39±4.87)分、(49.33±4.42)分、(187.97±12.21)分,均高于对照组的(44.15±4.26)分、(42.17±5.02)分、(45.02±3.94)分、(174.02±10.32)分,差异有统计学意义(P0.05),两组患者的社会功能得分比较无明显差异(P0.05)。结论:微波理疗可有效促进阑尾炎患者术后康复,减轻患者术后疼痛程度,降低术后并发症的发生率,并可有效改善患者术后的生活质量。     

重度烧伤患者应用重组人生长激素治疗的临床效果

目的:研究重组人生长激素对重度烧伤的应用治疗效果。方法:选取重度烧伤患者42例。根据随机数表法,将所有患者分为观察组(n=21)和对照组(n=21),观察组在对照组的基础上给予重组人生长激素治疗。结果:对照组术后24 h血红蛋白及总蛋白水平均低于实验组,差异无统计学意义(P0.05);对照组术后1周血红蛋白水平为(95.57±11.41)g/L,低于实验组的(137.91±14.29)g/L(t=3.726,P0.001);对照组术后2周血红蛋白水平为(80.89±11.38)g/L,低于实验组的(131.28±13.47)g/L(t=3.917,P0.001);实验组术后1周总蛋白水平为(61.47±5.19)g/L,高于对照组的(39.18±2.76)g/L(t=3.927,P0.001);实验组术后2周总蛋白水平为(55.78±6.38)g/L,高于对照组的(36.81±5.17)g/L(t=3.847,P0.001)。实验组术后24h的TNF-α和IL-6高于对照组,差异无统计学意义(P0.05);实验组术后2周的TNF-α、IL-6均明显低于对照组,差异有统计学意义(P0.001);实验组术后2周的TNF-α、IL-6均明显低于对照组,差异有统计学意义(P0.001);观察组的住院时长为(47.82±7.46)天,显著低于对照组的(79.36±8.10)天(t=4.275,P0.001);观察组的供皮区、植皮区、深Ⅱ度痂下愈合时间均显著低于对照组的,差异有统计学意义(P0.001)。结论:rh GH对重度烧伤的疗效非常显著,值得在临床中推广。